Income statement
AUD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 51M | 65M | 60M | 62M | 44M |
| Gross Profit | 31M | 46M | 12M | 22M | 10M |
| Operating Income | 11M | 6M | 3M | 15M | 5M |
| EBITDA | 17M | 10M | 8M | 18M | 8M |
| Net Income | 10M | 5M | 5M | 10M | 7M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$1.89
+0.00% today
1Y Change
+96.88%
Window
Jun 25, 2025 → Jun 16, 2026
Coverage: 245 bars · Jun 25, 2025 → Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Cogstate Limited (COGZF) is a Healthcare stock with a market cap of $290.00M and listed on OTC. The stock last traded around $1.89 and up 96.9% across the available one-year price window (Jun 25, 2025 → Jun 16, 2026). Baseline metrics include revenue growth of -22.0%, EPS growth of +23.3%, a dividend yield of 0.9%. What stands out right now is revenue -22.0%, EPS +23.3%, free cash flow +115.6% with operating margin 22.7% and ROIC 22.4%. The dividend is present but secondary, with a yield around 0.9%. Valuation is more restrained than many high-expectation growth names at P/E 19.8 and price/sales 4.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines COGZF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
COGZF
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
COGZF Max Drawdown
-35.24%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for COGZF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$43.8M
-29.4% YoY
FY Net Income
$7.0M
-32.3% YoY
Free Cash Flow
$17.2M
+101.8% YoY
Revenue Growth
-22.0%
EPS Growth
+23.3%
Gross Margin
36.1%
Net Margin
20.0%
Income statement
AUD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 51M | 65M | 60M | 62M | 44M |
| Gross Profit | 31M | 46M | 12M | 22M | 10M |
| Operating Income | 11M | 6M | 3M | 15M | 5M |
| EBITDA | 17M | 10M | 8M | 18M | 8M |
| Net Income | 10M | 5M | 5M | 10M | 7M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 36M | 30M | 13M | 18M | 18M |
| Total Assets | 65M | 58M | 81M | 85M | 68M |
| Total Liabilities | 17M | 17M | 25M | 37M | 39M |
| Shareholder Equity | 48M | 41M | 57M | 48M | 29M |
| Total Debt | 470K | 673K | 569K | 2M | 2M |
| Net Debt | -35M | -29M | -12M | -16M | -16M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
22M
+60.6% YoY
Capital Expenditures
4M
+11.1% YoY
Free Cash Flow
17M
+101.8% YoY
Key ratios
Gross Margin
36.1%
Operating Margin
22.7%
Net Margin
20.0%
ROE
29.1%
Debt / Equity
0.01x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.